From This Day Forward,

The first and only approved single molecule that activates the glucose dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors in the body.
Actor portrayal of an adult woman with type 2 diabetes
Limitations of Use
- Mounjaro has not been studied in patients with a history of pancreatitis.
- Mounjaro is not indicated for use in patients with type 1 diabetes mellitus.
Discover Once-Weekly Mounjaro: In a New Class of T2D Treatment1
The first and only approved single molecule that activates the GIP and GLP-1 receptors in the body1
GIP=glucose-dependent insulinotropic polypeptide; GLP-1=glucagon-like peptide-1; T2D=type 2 diabetes.
MORE
Superior A1C reduction across clinical trials1*
*Across the five phase 3 SURPASS studies, mean reductions in A1C with Mounjaro ranged from 1.8% to 2.1% for the 5-mg dose, 1.7% to 2.4% for the 10-mg dose, and 1.7% to 2.4% for the 15-mg dose vs 0.1% to 1.9% for comparators. p<0.05 for Mounjaro 5 mg vs study comparators, adjusted for multiplicity.1
THE RESULTS
Unmatched weight results across clinical trials1†
Mounjaro is not indicated for weight loss.
Change in weight was a secondary endpoint.
†Across the five phase 3 SURPASS studies, mean reductions in body weight ranged from 12 lb to 17 lb for the 5-mg dose, 15 lb to 21 lb for the 10-mg dose, and 17 lb to 25 lb for the 15-mg dose. For comparators, the change in weight ranged from a mean gain of 4 lb to a mean reduction of 13 lb. p<0.05 for superiority vs. study comparators, adjusted for multiplicity.1
THE DATA
Select Important Safety Information
WARNING: RISK OF THYROID C-CELL TUMORS
In both male and female rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Mounjaro causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.
Mounjaro is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Mounjaro and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Mounjaro.

Help your patients get off to a good start on Mounjaro
FIND OUT MOREReferences:
- Mounjaro. Prescribing Information. Lilly USA, LLC.